Companies › C4 Therapeutics
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cemsidomide | – | Phase 2 | Multiple Myeloma; Multiple Myeloma (MM) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04756726 | Cemsidomide | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT07280013 | Cemsidomide | Phase 1 | Multiple Myeloma (MM) | Oncology | Dec 2028 |
| NCT07284758 | Cemsidomide | Phase 2 | Multiple Myeloma | Oncology | Mar 2030 |
Cash and short-term investments of $275m on 2026-09-30; operating cash outflow about $77m a year; runway about 43 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Faeth Therapeutics Puma Biotechnology Black Diamond Therapeutics Kyntra Bio Shanghai Guangsheng Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.